A5012395020- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Hematopoietic Stem Cell Transplantation
- Histone Deacetylase Inhibitors Research
- Retinoids in leukemia and cellular processes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Multiple Myeloma Research and Treatments
- DNA Repair Mechanisms
- Neutropenia and Cancer Infections
- PARP inhibition in cancer therapy
- Protein Degradation and Inhibitors
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Immunotherapy and Immune Responses
- Lymphoma Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Cancer-related Molecular Pathways
- Cancer-related gene regulation
- Immune Cell Function and Interaction
- Cancer Treatment and Pharmacology
- Hedgehog Signaling Pathway Studies
- Hemoglobinopathies and Related Disorders
Sidney Kimmel Cancer Center
2010-2025
Johns Hopkins University
2015-2024
Sidney Kimmel Comprehensive Cancer Center
2015-2024
Johns Hopkins Medicine
2001-2022
Johns Hopkins Hospital
1986-2021
Christiana Care Health System
2020
The Ohio State University
2018
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2018
Memorial Sloan Kettering Cancer Center
2018
University of Baltimore
2010-2015
Glasdegib is a Hedgehog pathway inhibitor. This phase II, randomized, open-label, multicenter study (ClinicalTrials.gov, NCT01546038) evaluated the efficacy of glasdegib plus low-dose cytarabine (LDAC) in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome unsuitable for intensive chemotherapy. 100 mg (oral, QD) was administered continuously 28-day cycles; LDAC 20 (subcutaneous, BID) 10 per 28 days. Patients (stratified by cytogenetic risk) were randomized (2:1)...
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, blast phase) usually diagnosed chronic phase. Tyrosine kinase inhibitor (TKI) therapy highly effective first-line treatment option for all patients with newly phase (CP-CML). The selection TKI should be based on risk score,...
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, blast phase) usually diagnosed chronic phase. Tyrosine kinase inhibitor therapy highly effective first-line treatment option for all patients with newly phase CML. This manuscript discusses recommendations outlined NCCN...
Purpose Recent advances in nonmyeloablative (NMA), related HLA-haploidentical blood or marrow transplantation (haplo-BMT) have expanded the donor pool. This study evaluated effect of age on NMA haplo-BMT outcomes patients 50 to 75 years. Patients and Methods A retrospective analysis was performed 271 consecutive with hematologic malignancies, years, who received NMA, T-cell–replete high-dose post-transplantation cyclophosphamide. Results The median 61 115 (42%) 59, 129 (48%) 60 69, 27 (10%)...
Composite endpoints that not only encompass mortality and relapse, but other critical post-transplant events such as graft-versus-host disease, are being increasingly utilized to quantify survival without significant morbidity after allogeneic blood or marrow transplantation. High-dose, post-transplantation cyclophosphamide reduces severe disease with transplantation, making composite this management particularly interesting. We retrospectively analyzed 684 adults hematologic malignancies...
Abstract Purpose: To evaluate efficacy and safety of venetoclax + azacitidine among treatment-naïve patients with IDH1/2-mutant (mut) acute myeloid leukemia (AML). Patients Methods: Data were pooled from enrolled in a phase III study (NCT02993523) that compared treated or placebo prior Ib (NCT02203773) where azacitidine. Enrolled ineligible for intensive therapy due to age ≥75 years and/or comorbidities. on received 400 mg orally (days 1–28) (75 mg/m2; days 1–7/28-day cycle). Results: In the...
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome resulting from a reciprocal translocation between chromosomes 9 and 22 [t9;22] that gives rise to BCR::ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, blast phase) usually diagnosed chronic phase developed countries. Tyrosine kinase inhibitor (TKI) therapy highly effective treatment option for patients with phase–CML. The primary goal TKI phase–CML prevent disease progression...
These NCCN Guidelines Insights summarize several key updates to the for Acute Myeloid Leukemia and discuss clinical evidence that support recommendations. The described in this article focus on acute promyelocytic leukemia (APL) section, featuring recommendations additional induction/consolidation regimens patients with low- or intermediate-risk APL, providing guidance maintenance strategies APL.
Acute myelogenous leukemia (AML) patients with FLT3/ITD mutations have an inferior survival compared to AML wild-type (WT) FLT3, primarily because of increased relapse rate. Allogeneic transplantation represents a postremission therapy that is effective at reducing the risk for many cases poor-risk AML. Whether or not allogeneic in first complete remission (CR) can improve outcomes remains controversial. Our institution has adopted policy pursuing transplantation, including use alternate...
Incorporation of cytarabine into DNA activates checkpoint kinase 1 (Chk1), which stabilizes stalled replication forks, induces S-phase slowing, and diminishes cytotoxicity. The selective Chk1 inhibitor SCH 900776 abrogates cytarabine-induced arrest enhances cytotoxicity in acute leukemia cell lines leukemic blasts vitro. To extend these findings to the clinical setting, we have conducted a phase I study 900776.Twenty-four adults with relapsed refractory leukemias received timed sequential,...
Purpose: After failure of hypomethylating agents (HMA), patients with myelodysplastic syndromes (MDS) have dismal survival and no approved treatment options.Patients Methods: We conducted a phase 1b investigator-initiated trial ipilimumab in higher risk MDS who failed HMAs. Patients received monotherapy at two dose levels (DL; 3 10 mg/kg) an induction followed by maintenance phase. Toxicities responses were evaluated CTCAE.4 IWG-2006 criteria, respectively. also performed immunologic assays...